Dyne Therapeutics, Inc. (DYN) is a pharmaceutical preparations company. 11 insider Form 4 filings in the last 90 days. Next earnings projected around 2026-11-04 from DYN's year-over-year reporting pattern (not yet company-confirmed). Fundamentals from SEC filings; prices are end-of-day.
Source: SEC EDGAR · fundamentalsEOD · as of 2026-10-23 close · delayed, not real-time, so no bid or askMarket cap = last close × filed share count. How the count is chosen
why is it moving // cited AI read
What’s behind DYN’s latest move — the size, how unusual the volume is, and the catalyst on the tape, explained and cited to the source.
CiteDyne Therapeutics, Inc. (DYN), us-gaap:NetIncomeLoss: -446 USD, fiscal year ended 2025-12-31. Form DEF 14A, accession 0001193125-26-173655, filed 2026-04-23. Source: SEC EDGAR XBRL companyconcept, https://data.sec.gov/api/xbrl/companyconcept/CIK0001818794/us-gaap/NetIncomeLoss.json
EPS (diluted)$-3.47-3.0% y/yFY⊙
EVIDENCE — filed/published fact
SourceSEC XBRL companyfacts
FieldEarningsPerShareDiluted
loading revenue mix…loading fair value band…loading price vs fair value…loading trailing returns…loading capital allocation…loading style box…loading dividend safety…loading smart money…loading classification peers…loading funds holding…loading jurisdiction…
fair value // DCF · reverse DCF · Graham — no black boxestimate, not a target
FAIR-VALUE RANGE
—
CURRENT PRICE
$15.62
TWO-STAGE DCF
—
8% growth for 10y, 2.5% terminal, 9% discount
GRAHAM NUMBERiBenjamin Graham's ceiling for a cautious buyer: the highest share price his 1949 rule allows, at 15 times earnings and 1.5 times book value combined. A yardstick, not a forecast.
Estimates, not targets. The DCF treats free cash flow as cash flow to equity and divides by shares (the common retail shortcut — it skips net debt and a full WACC), so it’s a sanity-check, not a valuation opinion. All inputs are from DYN’s SEC filings; change any assumption above and the numbers update live. Educational only — not investment advice.
research brief // the filing-grounded overview + SWOTNEW
A plain-English read on DYN plus an auto-SWOT — built from DYN's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
research committee // bull vs bear, from the filingsNEW
Four AI analysts — a bull, a bear, a risk manager, and a PM — debate DYN using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
CiteDyne Therapeutics, Inc. (DYN), us-gaap:EarningsPerShareDiluted: -3.47 USD per share, fiscal year ended 2025-12-31. Form 10-K, accession 0001193125-26-084178, filed 2026-03-02. Source: SEC EDGAR XBRL companyconcept, https://data.sec.gov/api/xbrl/companyconcept/CIK0001818794/us-gaap/EarningsPerShareDiluted.json
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
filings & insider activity // official11 FORM 4 / 90D
As filed. We do not recategorize line items. Each chart plots one XBRL concept exactly as DYN tagged it: net income us-gaap:NetIncomeLoss, EPS us-gaap:EarningsPerShareDiluted, period by period; a period the company did not tag on its own is left out, not estimated. A figure that disagrees with the filing is a bug in our extraction, not a policy, and we fix it: report a mismatch.
No tracked institution reported a position in DYN in the latest 13F round.
Funds holding DYN // SEC Form NPORT-P, not a licence
3 of 39 funds we scan hold DYN
Every registered fund files its complete portfolio with the SEC. These weights come from those filings, so each one carries the period it describes. Holdings are quarterly and filed in arrears — the figures below are as of 2026-06-30, not today.
Fund
Weight
As of
IWMiShares Russell 2000 ETF
0.10%
2026-06-30
ITOTiShares Core S&P Total US Stock Market ETF
<0.01%
2026-06-30
VTIVanguard Total Stock Market ETF
<0.01%
2026-06-30
Drawn from 39 large US equity funds we scan, not every fund in existence, so a missing fund means we do not scan it rather than that it holds none. Holdings are joined to tickers by issuer name, which does not resolve every position; what that misses is published.
smart money // insiders vs institutionstwo clocks, not one signal
insider trades through · Form 4 as filed, 13F quarterly · SEC Form 4 and Form 13F-HR
Insiders onlyInsider activity on DYN, with no 13F position changes in the latest round.
INSIDERS · FORM 4
1 buy · 18 sell
Net −$113.8M. Open-market trades only — grants and option exercises are excluded, because they are compensation rather than a decision to buy. 17 of the sales were set up in advance under a Rule 10b5-1 plan.
INSTITUTIONS · 13F
0 adding · 0 trimming
0 tracked funds hold $0K.
From SEC Form 4 and 13F filings. Both are backward-looking disclosures on different reporting clocks, and neither predicts price. Educational information only — not investment advice.
earnings center DYN // expectation vs reality
NEXT REPORT · confidence engine★★★★★HIGH CONFIDENCE~ Nov 4 estProjected from year-over-year pattern · usually within ~3 days
▸24 historical earnings 8-Ks (Item 2.02) on file
▸Reports on a ~91-day quarterly cadence (+/-8d)
▸Usually reports on a Thursday (58% of quarters)
▸No typical report time: the last 8 results filings split 5 before the open, 3 after the close
▸Last report filed 2026-07-29, accepted 4:35 PM ET
Projected from DYN's own SEC 8-K filing history — the year-over-year reporting pattern (about 47% land the exact day, about 91% within a week, measured across 4,713 past reports). No analyst estimates and nothing invented, and every confirmed date links to the source it came from, so you can check it yourself. It upgrades the momentDYN files or announces.
The BreakdownEARNINGSdeterministic · from filings
DYN has sold off after 5 of its last 8 earnings reports.
Typical move±7.0%
Average move±9.8%
Biggest earnings pop+21.4%
Biggest earnings drop-15.4%
Each figure is one earnings reaction — how much DYN moved from the closing price the day before a report to the close the day after. Based on its last 8 reports.
Large earnings reactions have been common.
DYN has traded lower after most recent earnings releases.
The average is inflated by its most volatile prints (+21.4% and -15.4%).
A more typical earnings reaction has been approximately ±7.0%.
Realized close-to-close history only — no options-implied move, no analyst estimates.
Of 18 sales in the last ~6 months, 17 were filed with the Rule 10b5-1 box checked, set up in advance under a written trading plan; 1 was filed without it.
what is new on file for DYN // four checks, each datedwhat was checked, not a judgement
1 of the 2 checks that ran found nothing new for DYN; 1 found something. 2 could not run.
Filings
NOT CHECKED
Newest 10-K, 10-Q or 8-K on record: the 8-K (Reg FD disclosure) filed 2026-09-29. When this list was stored is not recorded for this company, so no "nothing since" claim is made.all filings →
Insider trades
NOT CHECKED
The Form 4 list for this company was read from source for this page build and that read time is not recorded, so no window claim is made. The insider panel below shows what was found.insider panel →
Congress trades
NOTHING NEW
No STOCK Act disclosure of a trade filed in the 30 days to 2026-10-25. None is on record in the feed. Members of Congress disclose a trade up to 45 days after it happens.⊙
25,977,390 shares short at the 2026-09-30 settlement, above the range of the 24 settlements in the 12 months before it (14,949,400 to 23,381,047, from 2025-09-30).⊙
INFERENCE — derived by arithmetic
SourceFINRA consolidated short interest, biweekly archive
FieldcurrentShortPositionQuantity
As of2026-09-30 settlement
HowThe latest settlement against the lowest and highest of the 24 settlements in the 12 months before it. Arithmetic on FINRA's figures; not split-adjusted.
Each event check looks back 30 days from the date its own source was stored, read or generated, never from the date this page was built. A check that finds nothing is a measurement of that window, not a forecast, and a check that cannot be dated does not make the claim at all.
fair value band // not built, 0 of 5 estimators rana range needs 2 estimators
None of the 5 estimators could run on DYN's filings.
One estimator is a point estimate, not a range, so no band and no valuation label are published for DYN. Below is everything that was checked, so the refusal can be read rather than taken on trust.
RAN
Nothing produced a value.
COULD NOT RUN
Median P/E: no price history available.
Median P/S: no price history available.
Median P/B: no price history available.
Median P/FCF: no price history available.
Two-stage DCF: free cash flow is not positive.
No fiscal year of price history was on record; the historical multiples need 5. No sector peer set is priced for DYN, so sector medians could not fill the gaps.
Where DYN is incorporated // the company’s own filing
Incorporated in Delaware, United States
Head office: Waltham, Massachusetts, United States · the company’s charter and its head office are in different states.
Source: the cover page of Dyne Therapeutics, Inc.’s 10-Q filed 2026-07-29, on EDGAR. Filings checked 2026-10-25. Incorporation is where the company’s charter was filed. It is not where the business operates or earns, which no filing cover states. How this works